Study on the mechanism of nausea and vomiting after percutaneous balloon compression for trigeminal neuralgia and preventative drugs

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072318

Enrollment

Unknown

Registered

2023-06-09

Start date

2023-06-08

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

trigeminal neuralgia

Interventions

control group:none

observation group A (midazolam + atropine):none

observation group B (midazolam + metoclopramide hydrochloride):none

observation group C (midazolam + diphenhydramine):none

observation group D (midazolam + dexamethasone):none

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: All the patients were selected based on the following criteria: (1) primary TN based on symptoms described by the International Headache Society Classification; (2)normal brain magnetic resonance imaging findings; (3)Age:50~85years (4) a pain visual analog scale (VAS) score over 7/10 and with a poor quality of life because of the pai3n

Exclusion criteria

Exclusion criteria: (1)Patients who can not cooperate (2)abnormal coagulation function

Design outcomes

Primary

Measure	Time frame
nausea and vomiting;5-hydroxytryptamine;substance P;dopamine;histamine;	—

Secondary

Measure	Time frame
VAS score;heart rate;herpes simplex;Headache;blood pressure;corneal reflex;	—

Countries

China

Contacts

Public ContactGao Liqin

The Second Hospital of Hebei Medical University

18203212623@163.com+86 182 0321 2623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026